7 completed, 1 active not recruiting, 1 recruiting, 1 withdrawn. 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 7, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
Follow pegcetacoplan: new trials by email Literature Review of pegcetacoplan trials Research Report on pegcetacoplan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients Pegcetacoplan - C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation | Phase 3 | Recruiting | Swedish Orphan Biovitrum | 30 | 2027-01-21 | 2026-11-09 |
| Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation Pegcetacoplan, Placebo - Delayed Graft Function, End Stage Renal Disease | Phase 3 | Withdrawn | Apellis Pharmaceuticals, Inc. | 2026-05-18 | 2026-09-02 | |
| Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe APL-2, Pegcetacoplan - Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 44 | 2025-10-24 | 2025-12-17 |
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan - C3G, IC-MPGN | Phase 3 | Active not recruiting | Apellis Pharmaceuticals, Inc. | 100 | 2023-05-29 | 2026-04-02 |
| A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) Pegcetacoplan, Placebo matching Pegcetacoplan - Cold Agglutinin Disease | Phase 3 | Completed | Swedish Orphan Biovitrum | 24 | 2022-10-20 | 2025-10-30 |
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan, Placebo - C3G, IC-MPGN | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 124 | 2021-11-12 | 2026-01-29 |
| An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD PEGCETACOPLAN (APL-2) - Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 792 | 2021-03-04 | 2026-10-28 |
| A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration APL-2, Sham Procedure - Geographic Atrophy | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 637 | 2018-08-31 | 2023-07-06 |
| Pegcetacoplan Long Term Safety and Efficacy Extension Study Pegcetacoplan - PNH | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 137 | 2018-08-27 | 2026-11-10 |
| Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Pegcetacoplan, Soliris - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 80 | 2018-06-14 | 2022-03-25 |
Geographic Atrophy (2) · Glomerulonephritis, Membranoproliferative (2) · Anemia, Hemolytic, Autoimmune (1) · Delayed Graft Function (1) · Hemoglobinuria, Paroxysmal (1) · Kidney Failure, Chronic (1) · Macular Degeneration (1)
Apellis Pharmaceuticals, Inc. (8) · Swedish Orphan Biovitrum (2)
Spain (8) · United Kingdom (8) · United States (8) · Canada (7) · France (7) · Germany (7) · Australia (6) · Brazil (6) · Italy (6) · Belgium (5) · Japan (5) · Netherlands (5) · Czechia (4) · Israel (4) · South Korea (4)
PMID 37707673, PMID 40720060, PMID 42133432, PMID 33730455, PMID 34445916, PMID 35796199, PMID 35869984, PMID 36055332, PMID 37314061, PMID 37865470, PMID 38315872, PMID 38573482, PMID 38593241, PMID 38722644, PMID 38727860, PMID 38814626, PMID 39079163, PMID 40285403, PMID 40388106, PMID 41337715, PMID 41533918
2023 (1)